Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 4/20 | 0.38 |
| ▸ | CDK2 | P24941 | 3/20 | 0.38 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.34 |
| ▸ | GSK3B | P49841 | 5/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.34 |
| ▸ | WNT1 | P04628 | 4/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2545074 | 1.00 | AKT1 (0.38) | AKT1CDK2TRPV3SYKFFAR1 | |
| SCHEMBL13286160 | 0.89 | AKT1 (0.37) | AKT1CDK2SYKGSK3BDYRK1A | |
| SCHEMBL2547009 | 0.86 | CDK2 (0.34) | AKT1CDK2SYKFFAR1GSK3B | |
| SCHEMBL3708146 | 0.86 | CDK2 (0.34) | AKT1CDK2SYKFFAR1GSK3B | |
| SCHEMBL2547011 | 0.86 | CDK2 (0.34) | AKT1CDK2SYKFFAR1GSK3B | |
| Trifluoroacetic Acid SCHEMBL2547822 | 0.85 | AKT1 (0.41) | AKT1CDK2SYKFFAR1 | |
| SCHEMBL12266702 | 0.85 | AKT1 (0.42) | AKT1CDK2 | |
| SCHEMBL3708170 | 0.84 | AKT1 (0.45) | AKT1CDK2SYKFFAR1GSK3B | |
| SCHEMBL1744296 | 0.84 | AKT1 (0.45) | AKT1CDK2SYKFFAR1GSK3B | |
| SCHEMBL2544075 | 0.83 | CDK2 (0.34) | AKT1CDK2SYKFFAR1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | TFEB, PCK2, JAK2 | AKT1 74/4885CDK2 151/4885TRPV3 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.